Servier and Vernalis Group have divulged new spirocyclohexane derivatives acting as induced myeloid leukemia cell differentiation protein Mcl-1 inhibitors and apoptosis inducers reported to be useful for the treatment of cancer, immunological disorders and autoimmune diseases.